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Abstract
Interactions of several microbial pathogens with the plasminogen system increase their invasive potential. In this study, we show that Strep-
tococcus agalactiae binds human plasminogen which can be subsequently activated to plasmin, thus generating a proteolytic bacterium. S. aga-
lactiae binds plasminogen via the direct pathway, using plasminogen receptors, and via the indirect pathway through fibrinogen receptors. The
glyceraldehyde-3-phosphate dehydrogenase is one of the S. agalactiae proteins that bind plasminogen. Presence of exogenous activators such as
uPA and tPA are required to activate bound plasminogen. Results from competitive inhibition assays indicate that binding is partially mediated
through the lysine binding sites of plasminogen. Following plasminogen binding and activation, S. agalactiae is able to degrade in vitro fibro-
nectin, one of the host extracellular matrix proteins. Moreover, incubation of S. agalactiae with either plasminogen alone, or plasminogen plus
fibrinogen, in the presence of tPA enhanced its virulence in C57BL/6 mice, suggesting that acquisition of plasmin-like activity by the bacteria
increase their invasiveness.
! 2007 Elsevier Masson SAS. All rights reserved.
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1. Introduction
Streptococcus agalactiae, also named group B Streptococcus
(GBS), is the major cause of bacterial sepsis, pneumonia and
meningitis in neonates and has emerged as an increasingly com-
mon cause of invasive disease in immunocompromised people
[1]. About 50% of infants born from infected women became
colonized with S. agalactiae during delivery and 1% of the col-
onized infants develop a severe GBS infection [1]. The main
route of neonatal infection is the ascending spread of S. agalac-
tiae into the amniotic fluid followed by the aspiration of contam-
inated amniotic fluid by the fetus. The bacteria can then colonize
and infect the lung, resulting in pneumonia. Subsequent trans-
migration of S. agalactiae across the epithelial border allows
the bacteria to invade the bloodstream and eventually reach
the meninges [1]. Invasion of host cells represents an important
mechanism in invasive S. agalactiae diseases [2,3].
Numerous human pathogens, including bacteria and viruses,
interact with the human plasminogen (Plg) system [4e6]. The
importance of these interactions for invasion and dissemination
in the infected host has been deduced from in vitro analysis
[4,6e9] and from in vivo studies employing Plg knock-out
mice [6,10e13]. In humans, Plg is converted to plasmin (Pl)
by Plg activators such as urokinase (uPA) and tissue-type
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plasminogen activator (tPA). However, under normal circum-
stances, plasminogen activator inhibitors (PAI) inhibit the acti-
vation of circulating Plg in blood. Pl is the key enzyme of the
Plg system that contributes to the degradation of fibrin and ex-
tracellular matrix proteins, like fibronectin, and activates latent
collagenases and metalloproteinases [5,6]. Plg activation and
Pl formation play an important role in a number of physiolog-
ical and pathological processes such as fibrinolysis, cell migra-
tion, and invasion [6,7,10e15]. Moreover, Plg activation has
been suggested as a critical component in establishing invasive
bacterial infections in host animals [4,6,10e14]. In particular,
Plg binding by Pseudomonas aeruginosa resulted in formation
of surface-associated plasmin that enhanced bacterial invasive-
ness [7]. More recently, Plg binding was shown to be essential
for the development of cutaneous lesions by Leishmania
mexicana [12].
In group A streptococci (GAS), Plg binding to bacterial sur-
face can be mediated by specific receptors (direct pathway) or
can involve the formation of a fibrinogen (Fg)-containing com-
plex (indirect or fibrinogen-dependent pathway) [9,16]. Direct
binding is mediated by the three known surface Plg receptors:
plasminogen-binding group A streptococcal M-like protein,
a-enolase, and glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH) [5,6,9]. Indirect Plg binding to GAS involves the for-
mation of a trimolecular complex consisting of Plg, streptoki-
nase and Fg that interacts with the cell surface via either Plg
or Fg receptors [9,16].
The GBS GAPDH is a moonlighting protein which, when
present at the cell surface, interacts with cytoskeleton and
extracellular matrix proteins and Plg [17]. This bacterium
also expresses a Fg receptor named FbsA that binds to human
Fg [18]. Therefore, GBS cells have the potential to bind Plg
through the direct and indirect pathways. However, the recruit-
ment of human Plg by GBS and the contribution of this process
to the invasive potential or virulence of this bacterium have not
been studied. In the present report, we provide the first evi-
dence for the acquisition of surface plasmin-like activity by
GBS and we further demonstrate the role of surface-bound
Plg in bacterial invasiveness and virulence. We have recently
described that GBS GAPDH is a virulence-associated immuno-
modulatory protein [19] and we show here that this enzyme is
also one of the GBS Plg-binding proteins.
2. Materials and methods
2.1. Bacterial isolate and growth conditions
Streptococcus agalactiae NEM316, isolated from a neonatal
blood culture [20], was grown in Brain-Heart Infusion (BHI)
broth or agar (Difco Laboratories, Detroit, MI, USA) at
37 "C. The complete genome sequence of this strain has been
determined [21].
2.2. Plasminogen labeling
Plasminogen (Sigma) was iodinated according to the Iodo-
gen method. Briefly, 200 ml of a plasminogen solution (28 mM
in 0.25 M phosphate buffer, pH 7.0) and 0.5 mCi of Na125I
(NEN) were added to a reaction tube coated with 500 mg of io-
dogen (Sigma) and the mixture was incubated in an ice bath
for 20 min. Labeled proteins were separated from the iodine
in a 5 ml Sephadex G-50 column. Based on the fact that at
least 90% of 125I-labeled plasminogen (125I-Plg) were precip-
itable in 20% trichloroacetic acid, its specific activity was es-
timated to be approximately 3 # 104 cpm/ng.
2.3. Plasminogen binding by S. agalactiae cells
To assess Plg binding to S. agalactiae cells, two binding as-
says were used.
2.3.1. 125I-Plasminogen binding to S. agalactiae cells
in suspension
S. agalactiae cells (z5 # 108), previously treated or not
with fibrinogen (1 mM) (Sigma), were incubated 2 h at 37 "C
with 125I-Plg (2.5 # 105 cpm). The cells were then centrifuged
and the unbound 125I-Plg present in the supernatant was re-
moved. The cell pellet was washed with PBS, centrifuged,
and the bound 125I-Plg was evaluated by measuring radioactiv-
ity in the pellet (gamma counter- Wallac 1470, Perkin Elmer).
The binding specificity was determined in a similar assay us-
ing a 100-fold molar excess of non-labelled Plg.
2.3.2. Plasminogen binding to S. agalactiae
immobilized in microtitre plate wells
S. agalactiae cells (z2 # 107 cfu/well) were seeded onto
a 96-well microtitre plate (Nunc, Roskilde, Denmark) and in-
cubated 30 min at 37 "C. Plate wells were blocked (1 h at
37"C) with 3% (w/v) BSA in 50 mM carbonate/bicarbonate
buffer pH 9.6 (Sigma). After blocking, the immobilized cells
were washed with PBS and incubated 1 h at 37 "C with vari-
ous concentrations of Plg (25, 50, 100, 300, 500, 1000 and
2000 nM) in PBS-BSA 1% or with whole, or PBS-diluted di-
luted (4% and 50%), human plasma (hP). After washing with
PBS, a further 1 h incubation was performed in the presence of
mouse anti-human Plg (Calbiochem, Madison, WI, USA)
(1:1000) in PBS-BSA 1%. The plates were washed again
and incubated 1 h at 37 "C in the presence of peroxidase-
labelled goat anti-mouse antibody (Southern Biotechnology
Associates, Birmingham, USA). The plates were then revealed
with orthophenylenediamine dihydrochloride (Sigma) and
H2O2 and, after 30 min at room temperature, the reaction
was stopped with 10% SDS and the absorbance was measured
at 450 nm with a Biotek Chromoscan.
Inhibition of Plg binding was studied in a similar assay
where S. agalactiae cells were incubated with Plg (500 nM)
in the presence of various 3-aminocaproic acid concentrations
(3-ACA: 0.01, 0.1, 1, 10, 100 and 1000 mM) (Sigma).
2.4. Plasminogen activation by S. agalactiae cells
The ability of S. agalactiae to activate Plg into plasmin was
monitored in a quantitative assay using the chromogenic sub-
strate D-Val-Leu-Lys-p-nitroanilide (S-2251) (Chromogenix,
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Milano, Italy). Approximately 5 # 108 S. agalactiae cells were
washed with PBS, mixed with 100 ml of human Plg (hPlg: 2, 5
and 10 mM) in the presence or absence of human tissue-type
plasminogen activator (tPA: 10 nM) (Calbiochem), or with
100 ml of human plasmin (Pl: 1 mM) (Sigma), and incubated
1 h at 37 "C. Similar experiments were performed in the pres-
ence of human Fg (1 mM), hPlg (1 mM) and tPA (10 nM) or
mouse Plg (mPlg; 1 mM) (Loxo, Dossenheim, Germany) plus
tPA (10 nM). After incubation, the cells were centrifuged,
washed, and resuspended in 400 ml of chromogenic substrate
D-Val-Leu-Lys-p-nitroanilide (S-2251: 400 mM). After 12 h in-
cubation at 37 "C, the cells were pelleted and the absorbance
of 100 ml of the supernatant fluid was measure at 405 nm in
a microplate reader.
To inhibit Plg activation, similar assays were performed
where S. agalactiae cells were incubated 1 h at 37 "C with
Plg (1 mM) plus tPA (10 nM) in the presence of various 3-
ACA concentrations (0.01, 0.1, 1, 10, 100 and 1000 mM).
The effect of a2-antiplasmin (a2-AP 100 nM) (Sigma), the
main physiological plasmin inhibitor, was also assessed as fol-
lows. Bacteria previously incubated with Plg (1 mM) and tPA
(10 nM) were incubated with S-2251 (400 mM) in the presence
or absence of a2-AP (100 nM). Assays where S. agalactiae
cells were incubated with PBS and soluble plasmin were in-
cluded as negative and positive controls, respectively.
2.5. Determination of proteolytic activity associated with
S. agalactiae grown in human plasma
Approximately 5 # 108 S. agalactiae cells were pelleted,
washed, resuspended in 500 ml of whole, or PBS-diluted
(4% and 50%) human plasma, or in 500 ml of plasminogen-
depleted human plasma (Calbiochem), and incubated 1 h at
37 "C. In the corresponding inhibition assays, z5 # 108 S.
agalactiae cells were incubated 1 h at 37 "C with 100% human
plasma in the presence of various 3-ACA concentrations (0.1,
1, 10, 100 and 1000 mM) (Sigma) or with a2-AP (100 nM).
Bacteria-associated proteolytic activity was determined using
the chromogenic substrate S-2251 as described above.
2.6. Degradation of human fibronectin
by S. agalactiae cells
Approximately 1 # 108 S. agalactiae cells were washed,
mixed with 100 ml of PBS, PBS-containing Plg (1 mM) plus
tPA (10 nM), or PBS-containing Fg (1 mM) plus Plg (1 mM)
plus tPA (10 nM), and incubated 1 h at 37 "C with gentle shak-
ing. After incubation, the cells were washed with PBS and re-
suspended in 100 ml Tris buffer [TriseHCl 50 mM; NaCl,
100 mM, and CaCl2, 5 mM; pH 7.0] containing or not human
fibronectin (Fn: 30 mg/ml) (Sigma) and further incubated 40 h
at 37 "C with gentle shaking. All samples were centrifuged
and 20 ml of supernatant were electrophoresed through
a 10% polyacrylamide SDS-PAGE. After electrophoresis, pro-
teins were either silver-stained or transferred to a nitrocellulose
membrane and probed with 1:1000 of rabbit anti-human fibro-
nectin antibody (Sigma).
2.7. Plasminogen-binding activity of S. agalactiae
sonicates and rGAPDH
Enzymatically active His-tagged recombinant GBS
GAPDH (rGADPH) was produced from Escherichia coli
BL21 (lDE3) harbouring pET28aUgapC as described previ-
ously [19]. S. agalactiae sonicates, rGAPDH, and Plg (positive
control) were subjected to SDS-PAGE (10% polyacrylamide)
and transferred to nitrocellulose membrane (Amersham Biosci-
ences, Uppsala, Sweden). The membrane was blocked with 3%
bovine serum albumin (BSA) in Tris Buffered Saline (TBS).
After washing in TBST (TBS containing 0.05% Tween 20),
the membrane was incubated overnight at 4 "C with hPlg
(4 mg/ml) in TBST-BSA 1%. After washing, a further 3 h incu-
bation with mouse anti-human plasminogen (1:1000) (Calbio-
chem) or anti-rGADPH (1:100) antibodies was performed. The
bound antibody was revealed by incubating the blot for 1 h
with alkaline-phosphatase-conjugated monoclonal goat anti-
mouse antibodies (Southern Biotechnology Associates). Stain-
ing was carried out with nitroblue tetrazolium dye (Promega,
Madison, WI, USA) and 5-bromo-4-chloro-3-indolyl phos-
phate (Promega) in AP buffer.
2.8. Mouse anti-rGAPDH IgG antibodies
Antibodies against rGAPDH were obtained from sera of
C57BL/6 mice immunized i.p. twice with a 3-week intervening
period with 20 mg of rGAPDH in a 1:1 PBS/alum suspension
(Aluminium hydroxide Gel; a kind gift of Dr Erik Lindblad, Bi-
osector, Frederickssund, Denmark). Sera of rGAPDH-immu-
nized mice were collected 30 days after the second
immunization and pooled for GAPDH detection by western
blot analysis.
2.9. Challenge infections and kinetics of the infection
Male C57BL/6 mice were purchase from Gulbenkian Insti-
tute of Science (Portugal). Animals were kept at the animal
facilities of the ICBAS during the time of the experiments.
S. agalactiae cells were grown in BHI broth to an OD600nm
of 0.120 (z107 CFU/ml). Aliquots (1 ml) of bacterial suspen-
sion were pelleted, washed twice with PBS buffer and resus-
pended in 100 ml of PBS, PBS-containing hPlg (1 mM) plus
tPA (10 nM), or PBS-containing human Fg (1 mM) plus hPlg
(1 mM) plus tPA (10 nM), and incubated 1 h at 37 "C. The
cells were pelleted, washed and resuspended in 1 ml of PBS.
C57BL/6 mice were injected i.p. with 5 # 106 CFU of PBS-
treated S. agalactiae cells, Plg-treated S. agalactiae cells, or
Fg- plus Plg-treated S. agalactiae cells. One and five days after
infection, the livers were aseptically removed, homogenized in
PBS, and serially diluted. Bacteria were plated onto BHI plate
containing streptococcus selective supplement (Oxoid, Hamp-
shire, England) and S. agalactiae CFU were enumerated after
48 h of incubation at 37 "C. The animal experiments were per-
formed according to EEC animal experimentation guidelines
Directive of 24 November 1986 (89/609/EEC) and Portuguese
rules (DL 129/92).
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2.10. Statistical analysis
The level of significance of the results in all groups of rats
was determined by one-way ANOVA, calculated with Micro-
soft Excel 2000 software. Significance was established at P
value of <0.05.
3. Results
3.1. Binding of human plasminogen
by S. agalactiae cells
The ability of S. agalactiae cells to bind human Plg was
tested following incubation of bacterial cells with labelled
125I-Plg plasminogen. As shown in Fig. 1A, S. agalactiae binds
Plg and this interaction is enhanced by pre-incubation of the
cells with Fg (z4 fold of increase) (P ¼ 0.0042). Binding of
Plg to bacterial cells was characterized in a saturation assay
using the microtitre plate method. As shown in Fig. 1B, the
binding affinity constant (or KM) calculated on the basis of
double-reciprocal plots was 80.67 % 10 nM. Moreover, Plg
binding to S. agalactiae cells can be inhibited in a dose-
dependent manner by 3-ACA which reduces the binding by
50% at a concentration of 10 mM (IC50) (Fig. 1C). These re-
sults indicate that GBS cells bind Plg specifically.
3.2. Activation of plasminogen by S. agalactiae cells
The ability of S. agalactiae cells to bind and activate hPlg
was measured using an assay based on the ability of plasmin
to cleave the chromogenic substrate S-2251 in a reaction that
can be followed spectrophotometrically at 405 nm. In this
experiment, the basal level of proteolytic activity was deter-
mined using S. agalactiae cells treated with PBS only. As
shown in Fig. 2, increased proteolytic activities could be
detected when bacteria were incubated with hPlg in the pres-
ence of human tPA. As expected, a dose-dependent activation
of Plg was observed (Fig. 2). Furthermore, the incubation of
bacterial cells with Plg plus tPA plus Fg increased twice the
proteolytic activity (Fig. 2). These results indicate that S. aga-
lactiae Plg binding can be mediated by the direct and indirect
pathways. Proteolytic plasmin-like activity was also detected
when plasmin was used instead of Plg, indicating that S. aga-
lactiae can bind directly the active enzyme (Fig. 2). In
contrast, incubation with Plg without a Plg activator did not
significantly modify the basal level of proteolytic activity
(PBS-treated cells), indicating that S. agalactiae did not se-
crete a Plg activator (Fig. 2). Similarly, no increase in proteo-
lytic activity was obtained when the cells were incubated with
a Plg activator alone (data not shown). Furthermore, S. aga-
lactiae cells also bind and activate murine Plg (Fig. 2). All
these experiments demonstrate that S. agalactiae cells have
the ability to bind Plg which can be subsequently activated
to plasmin.
3.3. Acquisition of proteolytic activity by S. agalactiae
after incubation with human plasma
Several microbes acquire proteolytic activity following in-
cubation with human plasma [6,9]. We therefore investigated
if S. agalactiae acquires proteolytic activity after incubation
with human plasma. An increase in proteolytic activity was
observed when S. agalactiae was incubated with human
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Fig. 1. Binding of plasminogen to S. agalactiae cells. Panel A. Binding of 125I-
plasminogen (125I-Plg) to S. agalactiae cells pre-incubated or not with fibrin-
ogen (Fg þ 125I-Plg). S. agalactiae cells were incubated with 125I-Plg for 2 h,
washed, and subjected to g-radioactive counting. Data are the means of three
replicates % SD and are representative of three independent experiments. As-
terisks denote results with mean differing significantly from control (bacteria
incubated with 125I-Plg) experiments: *P < 0.05. Panel B. Binding of plasmin-
ogen to S. agalactiae cells using a microtitre plate method. S. agalactiae cells
were exposed to plasminogen, incubated with anti-Plg antibody, and revealed
with peroxidase-labelled anti-Ig (H þ L) antibody. The insert shows a double
reciprocal plot of 1/bound against 1/added plasminogen and KM was &1/x.
Data are the mean of three replicates % SD and are representative of three in-
dependent experiments. In this example, the KM was 87.8 nM with r
2 value
0.99. Panel C. Inhibition of plasminogen binding to S. agalactiae cells by
the lysine analogue 3-aminocaproic acid (3-ACA). Binding was measured us-
ing various 3-ACA concentrations (0.1; 1; 10; 100 and 1000 mM) using a mi-
crotitre plate method, as described above. Data are the mean of three
replicates % SD and are representative of three independent experiments.
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plasma as compared with PBS-treated bacteria and this effect
was dependent upon the concentration of plasma utilized
(Fig. 3A). These results are in agreement with those of the
binding assay which showed that incubation of GBS cells
with increased concentrations of human plasma have in-
creased Plg binding (Fig. 3B). To demonstrate that the
proteolytic activity acquired by the S. agalactiae cells after
incubation with human plasma is due to binding and activa-
tion of Plg, we have similarly assayed GBS cells incubated
with plasminogen-depleted human plasma. As shown in
Fig. 3A, no increase in proteolytic activity was observed
after incubation of GBS cells with plasminogen-depleted
human plasma.
3.4. Degradation of human fibronectin by S. agalactiae
cells with a surface proteolytic plasmin-like activity
The ability of S. agalactiae cells previously incubated with
Plg (direct pathway) or with Fg plus Plg (indirect pathway) in
the presence of tPA to degrade the extracellular matrix protein
fibronectin was demonstrated in vitro (Fig. 4). Following elec-
trophoresis, fibronectin and fibronectin degradation products
were specifically detected with anti-fibronectin antibodies
(Fig. 4B, lanes 2, 4, 6, 7 and 8) and by silver staining
(Fig. 4A, lanes 2, 4, 6, 7 and 8). In this experiment, human fi-
bronectin was degraded by bacteria incubated with Plg plus tPA
(Fig. 4, lane 4), or with Fg plus Plg plus tPA (Fig. 4, lane 6), but
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not with cells treated only with PBS (negative control). Our re-
sults demonstrate that S. agalactiae can interact with plasmin-
ogen to increase its surface-associated proteolytic activity
although we have shown that this bacterium cannot activate
this precursor. It is conceivable that, when bound to the bacte-
rial surface, plasminogen is subject to a conformational change
that enables its activation by activators present in plasma such
as uPA and tPA.
3.5. Inhibition by 3-aminocaproic acid and
a2-antiplasmin of proteolytic activity
acquired by S. agalactiae
Plasminogen kringle domains often mediate interactions
with lysine residues of cellular receptors [5]. To evaluate their
possible involvement in the interaction of plasminogen with S.
agalactiae, a binding assay was carried out in the presence of
3-ACA, a lysine analogue, known to inhibit the binding of
plasminogen by competing with lysine-binding-sites. We
also investigated the effect of a2-AP, the main physiological
inhibitor of plasmin. As shown in Fig. 5, 3-ACA, but not a2-
AP, decreased the proteolytic activity of GBS cells incubated
with Plg which indicates that lysine residues are involved in
the Plg binding. This inhibition was dose-dependent (data
not shown) and reach a maximum of nearly 50% in the pres-
ence of 10 mM 3-ACA. To assess the role of these inhibitors in
the blood, S. agalactiae cells were incubated with hP in the
presence of various concentrations of 3-ACA and a2-AP.
Again, a dose-dependent inhibition of proteolytic activity
was observed in the presence of increasing concentrations of
3-ACA (data not shown) reaching a maximum of nearly
50% inhibition in the presence of 500 mM of inhibitors
(Fig. 5A), but no inhibition was observed with a2-AP
(Fig. 5B). In control experiment, we showed that a2-AP effi-
ciently inhibited the proteolytic activity of Pl when present
in fluid phase (Fig. 5B). The lack of inhibition with a2-AP ob-
served (Fig. 5B) when S. agalactiae cells were pre-incubated
with Plg, or with human plasma, might indicate that this broad
spectrum proteinase inhibitor did not inactivate plasmin when
this enzyme is already bound to bacterial surface, as reported
for other pathogens [6,9,15,16].
3.6. Analysis of plasminogen-binding
S. agalactiae proteins
To demonstrate the binding/interaction of hPlg with S. aga-
lactiae proteins, bacterial sonicate and purified rGAPDH were
separated by SDS-PAGE and transferred onto nitrocellulose
membranes which were incubated in the presence of Plg. Spe-
cific interactions of Plg with GBS proteins were detected by
immunoblot using mouse anti-human Plg antibody. In this
analysis, Plg was used as a negative control.
Several bands were detected in the bacterial sonicate indicat-
ing that various S. agalactiae proteins specifically interact with
Plg (Fig. 6). Interestingly, our analysis demonstrated that
rGAPDH bound Plg and, consistently, using anti-GAPDH anti-
bodies, GADPH (45 kDa) was identified on the basis of its im-
munoreactivity and electrophoretic mobility as one of the GBS
proteins present in the bacterial sonicate that interacts with Plg.
In control experiments, we demonstrated that Plg antibodies did
not react with proteins of GBS sonicate. Thus, as previously
shown for Group A streptococci, surface-associated GBS
GAPDH can recruit Plg. The fact that the GBS Plg receptors
have retained their binding capacity following electrophoresis
under denaturing conditions suggests that they are structurally
stable.
3.7. Enhancement of S. agalactiae virulence in C57BL/6
mice after bacterial incubation with human plasminogen
or human fibrinogen plus plasminogen
The ability of bacteria to interact with the human Plg sys-
tem and to recruit an unregulatable form of plasmin at its sur-
face has been reported to be important for the development of
A B
Silver staining anti-fibronectin
antibodies
1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8
Fibronectin
degradation
products
Fig. 4. Degradation of human fibronectin by S. agalactiae cells. Bacteria were incubated with: lane 1; PBS; lane 2, PBS plus fibronectin (1 mM); lane 3, plasmin-
ogen (1 mM) plus tPA (10 nM); lane 4, fibronectin (1 mM) plus plasminogen (1 mM) plus tPA (10 nM); lane 5, fibrinogen (1 mM) plus plasminogen (1 mM) plus tPA
(10 nM); lane 6, fibronectin (1 mM) plus fibrinogen (1 mM) plus plasminogen (1 mM) plus tPA (10 nM); lane 7, fibronectin (1 mM) only; and lane 8, fibronectin
(1 mM) plus plasmin (1 mM). After washing with PBS, the samples were incubated (lanes 2, 4, 6) or not (lanes 1, 3, and 5) with fibronectin (30 mg/mL) in buffer
(TriseHCl 50 mM, NaCl 100 mM and CaCl2 5 mM, pH 7.0). Plasmin plus fibronectin (lane 8) was included as a positive control. Following digestion, the samples
were subjected to electrophoresis through a 10% polyacrylamide gel containing SDS and the proteins were transferred to a nitrocellulose membrane and probed
with rabbit anti-human fibronectin antibody (Panel B) or were silver-stained (Panel A).
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a more invasive phenotype [7,10e14]. In order to evaluate
whether S. agalactiae cells displaying surface plasmin-like ac-
tivity were more invasive, groups of C57BL/6 mice (a mouse
strain resistant to S. agalactiae infection; authors’ unpublished
data) were inoculated i.p. with 5 # 106 CFU of S. agalactiae
cells treated with PBS, PBS-containing Plg plus tPA, or PBS-
containing Fg plus Plg plus tPA. The numbers of S. agalactiae
CFU were assessed in the liver of each group of infected mice
one and five days after the bacterial challenge. One day after
infection (Fig. 7A), the livers of the mice infected with
S. agalactiae cells pretreated with Plg, or with Fg plus Plg,
were more colonized than those of the control group
(Fig. 7). Five days after infection (Fig. 7B), all mice from
the control group have cleared the bacteria whereas those in-
fected with S. agalactiae cells treated with Plg, or with Fg
plus Plg, remained heavily colonized. Furthermore, a higher
liver colonization was observed in mice infected with S. aga-
lactiae cells incubated with Plg plus Fg than in mice infected
with bacteria incubated with Fg only (Fig. 7). These results
demonstrated that GBS invasiveness is greatly enhanced if
bacteria were incubated with Plg prior to infection.
4. Discussion
The ability of invasive pathogens to interact with the host
fibrinolytic system through Plg and to capture an unregulable
form of plasmin on the bacterial surface is thought to be a com-
mon virulence strategy that facilitates invasiveness through tis-
sue barriers [4,6e8,10e14]. Plg binding and its subsequent
activation to plasmin turn bacteria into proteolytic organisms.
For a wide range of pathogens, the use of in vitro and/or in
vivo animal models has demonstrated that Plg binding is crit-
ical for the process of invasiveness and establishment of the
infection [7,10e14]. In this study, we demonstrated for the
first time that S. agalactiae can recruit human Plg and that
the bound protein can be converted into an active protease
by natural plasma activators. Upon activation, surface-bound
Plg was shown, in vitro, to be able to degrade fibronectin,
one of the main proteins of extracellular matrix. We also dem-
onstrated that S. agalactiae cells pre-incubated with Plg or
with Fg and Plg in the presence of tPA, were more virulent
in an i.p. mouse infection model.
In vitro monitoring of the proteolytic activity at S. agalac-
tiae surface revealed an increased activity in bacteria pre-
incubated with Plg or Fg plus Plg in the presence of tPA,
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Fig. 5. Inhibition of plasminogen activation by 3-ACA and a2-antiplasmin. S.
agalactiae cells were incubated with PBS, PBS-containing plasminogen (Plg,
1 mM) plus tPA (10 nM), PBS-containing plasminogen plus fibrinogen (Plg,
1 mM; Fg, 1 mM) plus tPA (10 nM), or with human plasma (hP). Inhibition
was carried out with 3-ACA (Panel A) or a2-antiplasmin (a2-AP, 100 nM)
(Panel B). In this later panel, fluid phase plasmin (Pl, 1 mM) was included
as a positive control. Bacteria were pelleted by centrifugation, washed, and
the enzymatic activity associated with the cell pellet was determined by hydro-
lysis of S-2251. Data represent the mean of triplicate samples % SD and are
representative of three experiments. Asterisks denote results with mean differ-
ing significantly from S. agalactiae cells incubated with Plg or human plasma:
*P < 0.05, **P < 0.001.
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Fig. 6. Binding of S. agalactiae sonicate proteins and recombinant GAPDH to
human plasminogen. S. agalactiae sonicate proteins, recombinant GAPDH
(rGAPDH), and plasminogen were electrophoresed through a 10% polyacryl-
amide gel containing SDS and electroblotted to nitrocellulose membrane.(A)
Blot was incubated with human plasminogen and probed with mouse anti-
human plasminogen serum (1:1000). Lane 1, plasminogen; lane 2, rGAPDH;
lane 3, S. agalactiae sonicate. (B) Blot was incubated with mouse anti-
GAPDH serum (1:100). Lane 1, rGAPDH, lane 2, S. agalactiae sonicate.
Both blots were revealed using AP-conjugated monoclonal goat anti-mouse
antibodies.
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human plasma, or plasmin. These results indicate that S. aga-
lactiae can recruit Plg in human blood and that the bound
enzyme can be then activated to plasmin by blood natural ac-
tivators. The acquired surface proteolytic plasmin-like activity
was higher when S. agalactiae cells were incubated with Fg
plus Plg plus tPA than with Plg plus tPA, showing the impor-
tant contribution of the indirect pathway in the acquisition of
S. agalactiae surface proteolytic activity. This increase in pro-
teolytic activity of GBS cells observed after Fg incubation is
in accordance with the results showing that pre-incubation of
bacteria with Fg enhances the Plg binding as also described
by others [22]. Two pathways for modulation of Plg receptors
have been characterized: (i) a protease-dependent pathway
based on the ability of the cleaved substrates to expose
Plg-binding sites on the cell surface and (ii) a protease-
independent pathway that may be initiated by growth factors,
chemokines or cytokines that alter the cell membrane and/or
cytoskeleton architectures to expose Plg binding sites [23].
It is thus conceivable that Fg binding to GBS can induce con-
formational changes leading to the exposure of Plg-binding
sites that, in turn, enhances Plg binding and increases the
Plg binding capacity of the GBS cells.
Like in group A streptococci [6,9,16], we show that GBS
recruits Plg using both the direct and the indirect binding path-
ways. However, unlike GAS, it does not secrete any detectable
activator of host Plg. Certain bacteria interact with the host Plg
activator system to activate Plg and to acquire a plasmin-like
proteolytic activity [6,10]. Moreover, it is worth mentioning
that either fibrin or Fg are positive effectors of Plg activation
[24]. Our results demonstrate that GBS binds Plg through bac-
terial cell-surface receptors but the Plg activation pathway(s)
used by this bacterium remains to be elucidated.
We have recently showed that GAPDH is a virulence-
associated protein [19]. In the present study, we identified
this enzyme as one of the GBS plasminogen binding protein.
These results are consistent with a previous report [17] demon-
strating that the GBS GAPDH is an enzyme that can be pres-
ent at the bacterial surface to interact in vitro with
plasminogen and fibrinogen. GAPDH has also been described
as a plasminogen receptor in Streptococcus suis [25] and as
a surface-displayed plasminogen-binding protein in Strepto-
coccus pneumoniae [26]. Recently, Boel et al. constructed
a GAS mutant unable to secrete GAPDH, the enzyme being
retained in the cytoplasm and/or in the membrane [27]. This
mutant strain displayed 5.5-fold less GAPDH activity, bound
significantly less plasminogen, adhered poorly to human pha-
ryngeal cells, and lost its innate antiphagocytic activity [27].
Further studies will ascertain whether the S. agalactiae
GAPDH is involved in the surface acquired plasmin-like activ-
ity in vivo. The indirect binding pathway involves the initial
binding of fibrinogen at the cell surface and the subsequent
recruitment of plasminogen and plasminogen activators to as-
semble a plasminogen activator complex [9,16]. Thus, all GBS
fibrinogen-binding surface proteins might be involved in the
indirect binding pathway, including the major GBS fibrinogen
binding protein FbsA [18] and the GAPDH [17]. This latter
enzyme can therefore mediate the acquisition of proteolytic
activity by S. agalactiae through both pathways.
Plg kringle domains often mediate interactions with lysine
residues in receptors [5]. The interaction of several pathogens
with the Plg system is commonly inhibited by 3-ACA, a ly-
sine analog. Our results showed that Plg binding and acqui-
sition of proteolytic activity by S. agalactiae by the direct
and indirect pathways can be almost entirely inhibited by
3-ACA indicating that Plg binding is mainly mediated
through lysine binding sites [24]. We have also shown that
the a2-AP, the main physiological plasmin inhibitor, could
not inhibit the proteolytic activity acquired by S. agalactiae
through direct and indirect pathways or following incubation
with human plasma. Immobilization of plasminogen onto ly-
sine-containing surfaces is associated with conformational
changes in the molecule making it more susceptible to
tPA-mediated activation and more resistant to physiological
inhibitors [28]. In this way, our results suggest the acquisi-
tion by S. agalactiae of an unregulated form of protease ac-
tivity, a finding already observed with other pathogens
[6,9,15,16].
Degradation of fibronectin in vitro was observed with S.
agalactiae cells pre-incubated with Plg plus tPA or with Fg
plus Plg plus tPA. Such a high proteolytic activity conferred
to GBS may promote in vivo alterations of the basal membrane
integrity and may enhance bacterial penetration in infected tis-
sues. The degradation of fibronectin observed in our study may
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Fig. 7. Enhancement of S. agalactiae virulence after incubation with plasmin-
ogen plus tPA or with fibrinogen plus plasminogen plus tPA. Colony-forming
units (CFUs) in the liver of C57BL/6 mice one (Panel A) and five days (Panel
B) after i.p. infection with 5 # 106 S. agalactiae cells treated with PBS
(Control), plasminogen plus tPA (Plg þ tPA) or fibrinogen plus plasminogen
plus tPA (Fg þ Plg þ tPA). Errors bars represent the standard deviation of
two independent experiments done with 6 animals for each strain studied.
ND, non-detected. *P < 0.05, **P < 0.001.
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also have an impact on the inflammatory process as fibronec-
tin-derived peptides are chemotactic for human monocytes
[29] and contribute to matrix metalloproteinase production
[30]. Consistently, we observed that incubation of S. agalac-
tiae with Plg plus tPA or with Fg plus Plg plus tPA enhanced
the virulence in an i.p. model of mouse infection. In this exper-
iment, 5 days after infection, the liver colonization was only
detected in the mice infected with bacterial cells treated
with Plg or with Fg plus Plg whereas a complete bacterial
clearance was observed in the mice infected with the PBS
treated bacteria. It is noteworthy the observation of a higher
colonization when S. agalactiae cells were incubated with
Fg plus Plg plud tPA in comparison to the one obtained in
the Plg plus tPA group. Taken together, these results suggest
that acquisition of plasmin-like activity by the bacteria might
increase their invasiveness.
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